Clinical Predictors of Chronic Chagasic Myocarditis Progression

Rodolfo Viotti, Carlos Vigliano, Bruno Lococo, Marcos Petti, Graciela Bertocchi, María G. Álvarez, and Alejandro Armenti

Servicio de Cardiología, Sección de Enfermedad de Chagas e Insuficiencia Cardiaca, Hospital Eva Perón, San Martín, Buenos Aires, Argentina.

Introduction and objectives. Previous prognostic studies of Chagas’ disease have focused on mortality associated with end-stage cardiopathy (i.e., heart failure). Our aim was to identify indicators of progression in early-stage Chagas’ heart disease.

Material and method. The study included 856 patients with 3 positive anti-Trypanosoma cruzi test results. Those with heart failure were excluded. Patients were divided into 3 clinical groups: those without heart disease (Group I); those with heart disease but without left ventricular enlargement (Group II); and those with left ventricular enlargement but without heart failure (Group III). The endpoint was progression to a more severe clinical stage or death due to cardiovascular disease. A Cox regression model was used to derive a clinical risk score from clinical, electrocardiographic and echocardiographic variables.

Results. At study entry, the patients’ mean age was 43.7 years. They were followed up for a mean of 8 years. The following were predictors of heart disease progression: age at entry (HR=1.05; 95% CI, 1.02-1.07; P<.001), left ventricular systolic diameter (HR=1.06; 95% CI, 1.04-1.09; P<.001), intraventricular conduction abnormalities (HR=1.85; 95% CI, 1.02-3.36; P=.04), and sustained ventricular tachycardia (HR=3.97; 95% CI, 1.65-9.58; P=.002). Treatment with benznidazole reduced the risk of progression (HR=0.40; 95% CI, 0.23-0.72; P=.002). The devised clinical risk score was effective in stratifying the likelihood of cardiopathy progression.

Conclusions. Specific clinical indicators and a derived clinical risk score can be used to predict the progression of chronic chagasic myocarditis in patients without heart failure.

Key words: Cardiopathy. Cardiac disease. Heart failure. Prognosis.

Indicadores clínicos de progresión de la miocarditis chagásica crónica

Introducción y objetivos. Los estudios de pronóstico efectuados sobre la mortalidad de la cardiopatía se han centrado en la etapa final de la enfermedad (insuficiencia cardiaca). Nuestro objetivo fue establecer los indicadores de progresión de la enfermedad de Chagas en estadíos tempranos.

Material y método. Se incluyó a 856 pacientes con 3 pruebas reactivas anti-Trypanosoma cruzi y se excluyó a los pacientes con insuficiencia cardiaca. Se utilizó la siguiente estratificación clínica: grupo I, sin cardiopatía; grupo II, con cardiopatía y sin dilatación del ventrículo izquierdo (VI); grupo III, con dilatación del VI, sin insuficiencia cardiaca.

El punto final de evaluación fue la progresión hacia un grupo clínico de mayor severidad o la muerte cardiovascular. Se incluyeron las variables clínicas, electrocardiográficas y ecocardiográficas en un análisis multivariado (Cox) y se construyó una puntuación de riesgo.

Resultados. La edad promedio fue de 43.7 años y el seguimiento de 8 años. La edad (hazard ratio [HR] = 1,05; intervalo de confianza [IC] del 95%, 1,02-1,07; p < 0,001), el diámetro sistólico del VI (HR = 1,06; IC del 95%, 1,04-1,09; p < 0,001), los trastornos de conducción intraventricular (HR = 1,85; IC del 95%, 1,02-3,36; p = 0,04) y la taquicardia ventricular sostenida (HR = 3,97; IC del 95%, 1,65-9,58; p = 0,002) fueron predictores de progresión de la cardiopatía. El tratamiento con benznidazol redujo el riesgo de progresión (HR = 0,40; IC del 95%, 0,23-0,72; p = 0,002).

La puntuación de riesgo construida estratificó adecuadamente la probabilidad de progresión de la cardiopatía.

Conclusions. Los indicadores clínicos y la puntuación propuesta pueden establecer el pronóstico de progresión de la miocarditis chagásica crónica sin insuficiencia cardiaca.

INTRODUCTION

Chagas disease is the single most important infectious cause of myocardials1; of the 15-20 million people infected in Latin America, some 25% suffer from this heart complication. The pathogenesis of chronic Chagas heart disease is not completely understood2, although the possible course of events (manifested only very slowly and progressively) is thought to involve the presence of the etiological agent Trypanosoma cruzi or its antigenic components (the DNA of the parasite) in cardiac tissue,3 an abnormal response on the part of the immune system which fails to control or cure the infection and acts as a mediator of cell damage,4 followed by diffuse or focal chronic myocarditis with progression towards myocardial fibrosis.5 From a clinical point of view, the disease has been classically described as passing through acute, indeterminate and chronic stages.6 Manifest cardiomyopathy is seen in adults who were infected during childhood.7 The presentation of chronic heart disease is polymorphic.8 Patients may suffer intraventricular conduction problems, ventricular arrhythmias, sinus node disease, segmentary lesions of the left ventricle (LV), enlargement and dysfunction of the LV with or without heart failure, or combinations of the above. The main causes of death are heart failure or sudden death—70% and 30% respectively of nearly all Chagas deaths.8,9

The prognostic studies undertaken so far have largely focused on mortality due to cardiomyopathy in the final stages of the disease (heart failure).10-13 In these studies, very important prognostic factors such as electrocardiographic variables and arrhythmias were not analyzed in conjunction with already established clinical variables. Other studies have focused on complex ventricular arrhythmias without taking into account the progress of the disease or non-arrhythmic variables of prognostic importance.14,15

The aim of the present study was to establish the prognostic indicators of the progression of heart disease in patients with indeterminate stage Chagas disease and with manifest cardiomyopathy but without heart failure.

MATERIALS AND METHODS

The patients in this study all had Chagas disease, as confirmed by 3 serological tests (the Machado Guerreiro test or ELISA, indirect haemagglutination, and immunofluorescence). Those presenting with concomitant heart disease (such as congenital heart disease) (n=4), high blood pressure (n=29), ischemia (n=8), other types of heart disease (n=3), or who were alcoholics (n=5), were excluded from the final sample (n=856). Those with enlargement of the LV and heart failure were also excluded since they were considered to be in the final stages (mortality among these patients was expected to be high); moreover, the prognostic factors pertinent to these patients have already been studied.16-17 On entry to the study, patients were stratified into different clinical categories: group I—no heart disease, reactive serology, electrocardiogram (ECC) normal, chest x-ray normal, LV diastolic diameter ≤57 mm; group II—manifest heart disease with no enlargement of the LV, reactive serology, ECC normal, chest x-ray normal, LV diastolic diameter ≤57 mm; group III—manifest heart disease with enlargement of the LV, reactive serology, abnormal ECC, chest x-ray showing evidence of cardiomegaly (cardiotoracic index >0,50), and/or LV diastolic diameter >57 mm, but with no sign of heart failure.

The electrocardiographic anomalies considered to be related to Chagasic cardiomyopathy were: complete right bundle branch block, anterior left bundle branch block, Lown grade II or higher ventricular extrasystole, areas of electrical inactivation, atrial flutter, atrial fibrillation, atrial tachycardia, sinus bradycardia ≤50 x’, sustained or non-sustained ventricular tachycardia, and type II second degree and third degree atrioventricular (AV) block. Patients who received a pacemaker during the study were also regarded as showing electrocardiographic abnormalities. These ECG abnormalities were significantly more common among patients with T cruzi antibodies than in uninfected individuals.18 During the screening phase of the study (the first 2 months), all patients were subjected to the following examinations: ECC, ergometry, chest x-ray, and an echocardiogram (two-dimensional, M mode). Once stratified according to their clinical characteristics, the patients were monitored and followed-up according to the protocols adopted by our department: group I—one appointment with ECC every 6-12 months, Holter monitoring or repetition of ergometry, and echocardiography in accordance with symptoms or changes in baseline ECC (or every 5 years); group II—one appointment with ECC every 4-6 months, Holter monitoring or repetition of ergometry, and echocardiography in accordance with symptoms or changes in baseline ECC (or every 5 years); group III—one appointment with ECC every 3 months, Holter monitoring or repetition of ergometry, and echocardiography in accordance with symptoms or changes in baseline ECC (or every 5 years), echocardiogram every 2 years. Patients who pro-

ABBREVIATIONS

ECC: electrocardiogram.
HR: hazard ratio.
LV: left ventricle.
gressed towards heart disease underwent an ECG monthly and an echocardiogram annually.

In the determination of indicators of the progression of chronic Chagasic cardiomyopathy, the end point (dependent variable) was taken as movement into a more severe clinical group or death due to cardiovascular causes (both defined as changes in clinical group). Such progression required the appearance of an ECG abnormality, enlargement of the LV, the appearance of heart failure, or death.

The prognostic importance of the following variables were determined with respect to heart disease progression: age at entry, etiological treatment with benznidazole 5 mg/kg/day for 30 days (undertaken before entry to the study), intraventricular conduction abnormalities, complete right bundle block, left anterior hemiblock, complete right bundle block associated with left anterior hemiblock and complete left bundle block, baseline heart rate at entry, ventricular extrasystole diagnosed in ECG monitoring or in ergometric tests, non-sustained ventricular tachycardia (diagnosed from the baseline ECG, ergometry testing or Holter monitoring), the systolic and diastolic diameters of the LV, the diastolic diameter of the left atrium, systolic dysfunction of the LV, and the presence of segmentary lesions of the LV detected by echocardiography (two-dimensional, M mode).

Clinical Risk Score

To establish the individual risk of the progression of chronic Chagasic cardiomyopathy, the hazard ratios (HR) obtained in multivariate analysis were transformed into scores reflecting their prognostic significance. For this, continuous variables were transformed into dichotomous variables, establishing a cut-off point representative of the risk.

Loss to Follow-up

During the study, 221 patients (26% of the total) were lost to follow-up, the majority because of internal migration. Postal appointments were sent to try to recover these patients 5 and 10 years into the study; 84 were recovered (38% of those originally lost). Median follow-up time was 4.9 years in those lost to follow-up; the interquartile range (25%-75%) was 1.8-7.7 years.

Statistical Analysis

The results for continuous variables were expressed as the mean and standard deviation (SD) or the median and interquartile range (25%-75%). Dichotomous variables were expressed as result/total. For univariate analysis, all variables recorded in the study were analyzed using the Cox proportional risk model and with respect to the dependent variable of change in clinical group. For multivariate analysis the Cox regression model was used. This included all the variables found to be significant (P<.05) in the univariate analysis. When collinearity was seen between 2 variables, the regression was repeated including both variables separately in order to assess their significance with respect to the dependent variable. Survival was analyzed using the Kaplan-Meier method; the log-rank test was used to determine significance. All calculations were performed using Statistix 7.0 Analytical Software and SPSS 6.1 Statistical Analysis Software for Windows (SPSS Inc).

The study protocol was approved by the Research and Ethics Committee of our institution. All patients gave their consent to be included in the study.

RESULTS

The mean age of the patients at entry was 43.7±10.8 years. Overall median follow-up was 8 years; the in-

<table>
<thead>
<tr>
<th>TABLE 1. Changes of Clinical Group and Deaths With Respect to Clinical Group at Entry to the Study</th>
</tr>
</thead>
<tbody>
<tr>
<td>Number of Patients at Entry</td>
</tr>
<tr>
<td>----------------------------</td>
</tr>
<tr>
<td>Group I</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Group II</td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td></td>
</tr>
<tr>
<td>Group III</td>
</tr>
<tr>
<td></td>
</tr>
</tbody>
</table>

Group I indicates patients without cardiomyopathy; group II, patients with manifest cardiomyopathy but no enlargement of the left ventricle; group III, patients with manifest cardiomyopathy and enlargement of the left ventricle.

TABLE 2. Univariate Analysis (Cox) of the Predictors of Change of Clinical Group*

<table>
<thead>
<tr>
<th>Variables</th>
<th>No Change in Group, n=782</th>
<th>Change in Group, n=74</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at entry to study, mean ± SD</td>
<td>46.18±10.76</td>
<td>49.04±8.49</td>
<td>1.00</td>
<td>0.86-1.36</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Baseline heart rate, median (25%-75%)</td>
<td>75 (60-86)</td>
<td>68 (60-86)</td>
<td>1.00</td>
<td>0.84-1.20</td>
<td>0.78</td>
</tr>
<tr>
<td>Diastolic diameter of the LV, median, mm (25%-75%)</td>
<td>48 (43-52)</td>
<td>56 (48.7-64)</td>
<td>1.00</td>
<td>0.82-1.36</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Systolic diameter of the LV, median, mm (25%-75%)</td>
<td>25 (24-33)</td>
<td>36 (28-49)</td>
<td>1.00</td>
<td>0.90-1.16</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Systolic diameter of the LA, median, mm (25%-75%)</td>
<td>33 (27-41)</td>
<td>38 (31-48)</td>
<td>1.00</td>
<td>0.80-1.34</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Etiological treatment.</td>
<td>318 (41)</td>
<td>19 (26)</td>
<td>1.00</td>
<td>0.72-1.43</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Intraventricular conduction abnormalities, %</td>
<td>312 (40)</td>
<td>58 (78)</td>
<td>1.00</td>
<td>0.78-1.38</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Ventricular extrasystoles, %</td>
<td>257 (33)</td>
<td>38 (51)</td>
<td>1.00</td>
<td>0.70-1.46</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Non-sustained ventricular tachycardia, %</td>
<td>30 (4)</td>
<td>5 (7)</td>
<td>1.00</td>
<td>0.53-2.07</td>
<td>.23</td>
</tr>
<tr>
<td>Sustained ventricular tachycardia</td>
<td>5 (0.6)</td>
<td>8 (11)</td>
<td>1.00</td>
<td>0.41-2.54</td>
<td>&lt;.0001</td>
</tr>
<tr>
<td>Segmental lesions of the LV</td>
<td>501 (66)</td>
<td>12 (16)</td>
<td>1.00</td>
<td>0.50-2.08</td>
<td>.32</td>
</tr>
<tr>
<td>Systolic dysfunction</td>
<td>34 (4)</td>
<td>20 (27)</td>
<td>1.00</td>
<td>0.43-2.04</td>
<td>&lt;.0001</td>
</tr>
</tbody>
</table>

*LA indicates left atrium; SD, standard deviation; LV, left ventricle.

TABLE 3. Multivariate Analysis (Cox) of the Predictors of Change in Clinical Group*

<table>
<thead>
<tr>
<th>Variables</th>
<th>Changes in Clinical Group</th>
<th>Hazard Ratio</th>
<th>95% CI</th>
<th>P</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age at entry to study</td>
<td></td>
<td>1.05</td>
<td>1.02-1.07</td>
<td>.000</td>
</tr>
<tr>
<td>Diastolic diameter of the LV</td>
<td></td>
<td>1.01</td>
<td>-</td>
<td>.065</td>
</tr>
<tr>
<td>Systolic diameter of the LV</td>
<td></td>
<td>1.06</td>
<td>1.04-1.09</td>
<td>.000</td>
</tr>
<tr>
<td>Systolic diameter of the LA</td>
<td></td>
<td>1.01</td>
<td>-</td>
<td>.05</td>
</tr>
<tr>
<td>Etiological treatment</td>
<td></td>
<td>0.40</td>
<td>0.23-0.72</td>
<td>.002</td>
</tr>
<tr>
<td>Sustained ventricular tachycardia</td>
<td></td>
<td>3.97</td>
<td>1.65-9.58</td>
<td>.002</td>
</tr>
<tr>
<td>Intraventricular conduction abnormalities</td>
<td></td>
<td>1.85</td>
<td>1.00-3.36</td>
<td>.04</td>
</tr>
<tr>
<td>Systolic dysfunction†</td>
<td></td>
<td>2.85</td>
<td>1.53-5.31</td>
<td>.001</td>
</tr>
</tbody>
</table>

*LA indicates left atrium; LV, left ventricle; CI, confidence interval.
†Figures show the curves to separate after four or 5 years of follow-up, reflecting the minimum length of time required to detect differences in the progression of chronic Chagasic cardiomyopathy.

**Clinical Risk Scores**

Those variables that were significant in multivariate analysis were used to construct individual clinical risk scores. For this, significant continuous variables were transformed into dichotomous variables. Thus, the systolic diameter of the LV was transformed into the variable systolic diameter of the LV ≥40 mm, and age at entry was transformed into age at entry ≥50 years. The scores assigned to each variable were: age at entry ≥50 years =2 points (HR=1.86), systolic diameter of the LV ≥40 mm =3 points (HR=5.09), intraventricular conduction abnormalities =2 points (HR=1.85), sustained ventricular tachycardia =3 points (HR=3.97), and etiological treatment with benznidazole =2 points (HR=0.4). Systolic dysfunction of the LV (HR=2.85) appears as an alternative to systolic diameter of the LV≥40 mm, and was accordingly assigned 3 points.
The maximum risk score on this scale is 10, a score of 0 represents no risk. Final scores were obtained by adding together the scores for each variable. For the variable “etiological treatment with benznidazole,” 2 points were subtracted from the total. Table 4 shows a number of risk score categories, the number of pa-

![Figure 1. Kaplan-Meier curves for patients with and without conduction abnormalities at entry to the study.](image1)

![Figure 2. Kaplan-Meier curves for patients who received and who did not receive benznidazole treatment.](image2)
The high mortality rate associated with cardiomyopathies of different etiology can be explained by a number of related and non-exclusive factors, including the extension of myocardial damage, the deterioration of heart function, and the appearance of lethal ventricular arrhythmias. Chronic Chagasic cardiomyopathy is different, however, to other kinds of heart disease. It is defined as a chronic myocarditis or a state of inflammation with periods of progression, changing in nature at certain moments with the unexpected appearance of complex ventricular arrhythmias. It is commonly accompanied by segmental lesions of the LV, whose association with ventricular arrhythmias is well known. Conduction abnormalities, especially in association with complete right bundle block and anterior left hemiblock, are also common (although not exclusive to this disease). Finally, the enlargement of the LV and the deterioration in overall systolic function which appears in the final stages of the disease is a route common to all cardiomyopathies advancing towards their final outcome. However, chronic Chagasic myocarditis also compromises the autonomic, sympathetic and parasympathetic nervous systems, which, in a context of inflammation, fibrosis and conduction abnormalities, is thought to be a factor in sudden death. This same damage to the autonomic nervous system determines the rare clinical appearance of uncompensated heart failure with bradycardia or normal heart rate (similar to beta-adrenergic block).

Patients in the indeterminate stage of Chagas disease or who suffer no cardiomyopathy generally have a good prognosis, but they can change group and even die, as occurred in the present cohort. The present results should be interpreted bearing in mind the composition of the patient sample—80% had no cardiomyopathy and fell into group 1, and 90% had either no or only mild cardiomyopathy at entry to the study (groups I and II). This starting point was important because it allows the progression of the disease to be followed from its early stages or, using the above terminology, from the indeterminate stage towards the appearance of manifest cardiomyopathy.

The only arrhythmia variable with prognostic value for the patients of the present study was the presence of sustained ventricular tachycardia. Neither ventricular extrasystoles nor self-limiting ventricular tachycardia were of predictive value. Other important variables such as the diastolic diameter of the LV, the systolic diameter of the left atrium and the existence of segmental lesions were not independently predictive either. Conduction abnormalities were found to be predictors of advancing disease independent of all echocardiographic findings. This result returns one to the hypothesis that bundle branch blocks are the electrical expression of the complex process defined as chronic myocarditis.

Etiological treatment with benznidazole was the only indicator of delay in the progression of cardiomyopathy. Our group and other authors have described the possible effects of this anti-T cruzi treatment on the clinical and serological course of the disease.

Changes in clinical severity group are a reliable measure of disease progression since they clearly reflect worsening heart disease; indeed, they have been used before in this context. The stratification of pa-
tients into clinical groups in this work was similar to that described by Kuschnir et al., with the incorporation of the diastolic diameter of the LV. This better differentiates patients with enlarged and normal size hearts.

The clinical risk score, calculated using the results of the multiple regression analysis, was useful for identifying risk groups with respect to the progression of cardiomyopathy. However, when used with individual patients it should only be regarded as a guide, as are score systems used to stratify the prognosis of other forms of heart disease.2,3,4

Chronic Chagas cardiomyopathy is a serious disease but it can be diagnosed early. Several indicators are available that should alert clinicians to the progression of the disease. Patients thus affected can be identified and given appropriate clinical attention.

REFERENCES